Cyclophosphamide Treatment Options

A collection of 2150 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.

Home

All Treatments

Cyclophosphamide

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05633615

Recruiting

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/17/2024

Locations: Banner University Medical Center - Tucson, Tucson, Arizona +75 locations

Banner University Medical Center - Tucson, Tucson, Arizona

University of Arizona Cancer Center-North Campus, Tucson, Arizona

Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Highlands Oncology Group - Rogers, Rogers, Arkansas

Highlands Oncology Group, Springdale, Arkansas

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

UCSF Medical Center-Parnassus, San Francisco, California

University of Florida Health Science Center - Gainesville, Gainesville, Florida

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Emory Saint Joseph's Hospital, Atlanta, Georgia

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho

Saint Luke's Cancer Institute - Meridian, Meridian, Idaho

Saint Luke's Cancer Institute - Nampa, Nampa, Idaho

Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho

University of Illinois, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Loyola University Medical Center, Maywood, Illinois

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

University of Kansas Cancer Center, Kansas City, Kansas

University of Kansas Cancer Center-Overland Park, Overland Park, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas

The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky

UofL Health Medical Center Northeast, Louisville, Kentucky

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

Bronson Battle Creek, Battle Creek, Michigan

Wayne State University/Karmanos Cancer Institute, Detroit, Michigan

Weisberg Cancer Treatment Center, Farmington Hills, Michigan

Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan

Trinity Health Grand Rapids Hospital, Grand Rapids, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

West Michigan Cancer Center, Kalamazoo, Michigan

Ascension Borgess Cancer Center, Kalamazoo, Michigan

Trinity Health Muskegon Hospital, Muskegon, Michigan

Corewell Health Lakeland Hospitals - Niles Hospital, Niles, Michigan

Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan

Corewell Health Reed City Hospital, Reed City, Michigan

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center, Saint Joseph, Michigan

Henry Ford Health Providence Southfield Hospital, Southfield, Michigan

Munson Medical Center, Traverse City, Michigan

University of Michigan Health - West, Wyoming, Michigan

University of New Mexico Cancer Center, Albuquerque, New Mexico

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

NYP/Weill Cornell Medical Center, New York, New York

University of Rochester, Rochester, New York

Wilmot Cancer Institute at Webster, Webster, New York

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Case Western Reserve University, Cleveland, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Providence Newberg Medical Center, Newberg, Oregon

Providence Willamette Falls Medical Center, Oregon City, Oregon

Providence Portland Medical Center, Portland, Oregon

Providence Saint Vincent Medical Center, Portland, Oregon

Oregon Health and Science University, Portland, Oregon

Geisinger Medical Center, Danville, Pennsylvania

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania

Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina

Medical University of South Carolina, Charleston, South Carolina

Prisma Health Cancer Institute - Easley, Easley, South Carolina

Prisma Health Cancer Institute - Butternut, Greenville, South Carolina

Prisma Health Cancer Institute - Faris, Greenville, South Carolina

Prisma Health Cancer Institute - Eastside, Greenville, South Carolina

Prisma Health Cancer Institute - Greer, Greer, South Carolina

Prisma Health Cancer Institute - Seneca, Seneca, South Carolina

Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee

University of Vermont Medical Center, Burlington, Vermont

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin

University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin

Medical College of Wisconsin, Milwaukee, Wisconsin

Froedtert and MCW Moorland Reserve Health Center, New Berlin, Wisconsin

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma

Learn More ›

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT02427620

Active Not Recruiting

This phase II trial studies how well ibrutinib, rituximab, and consolidation chemotherapy consisting of cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, and cytarabine work in treating young patients with newly diagnosed mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the can... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

12/17/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma

Learn More ›

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

NCT04109066

Completed

A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/16/2024

Locations: Local Institution - 0136, Mobile, Alabama +239 locations

Local Institution - 0136, Mobile, Alabama

Local Institution - 0052, Greenbrae, California

Local Institution - 0051, Whittier, California

Local Institution - 0182, Stamford, Connecticut

Local Institution - 0150, Jacksonville, Florida

Local Institution - 0097, Miami, Florida

Local Institution - 0149, Pensacola, Florida

Local Institution - 0120, Tallahassee, Florida

Local Institution - 0054, Athens, Georgia

Local Institution - 0107, Atlanta, Georgia

Local Institution - 0056, Columbus, Georgia

Local Institution - 0221, Chicago, Illinois

Local Institution - 0227, Fort Wayne, Indiana

Local Institution - 0222, Topsham, Maine

Local Institution - 0146, Bethesda, Maryland

HCA Midwest Division, Kansas City, Missouri

Local Institution - 0109, Florham Park, New Jersey

Local Institution - 0050, Hackensack, New Jersey

Local Institution - 0180, New Brunswick, New Jersey

Local Institution - 0181, Albuquerque, New Mexico

Local Institution - 0041, Bronx, New York

Local Institution - 0283, Charlotte, North Carolina

Duke Cancer Institute, Durham, North Carolina

Local Institution - 0053, Cleveland, Ohio

Local Institution - 0218, Nashville, Tennessee

Local Institution - 0121, Fort Worth, Texas

Local Institution - 0224, Fairfax, Virginia

Local Institution - 0122, Fredericksburg, Virginia

Virginia Cancer Institute, Richmond, Virginia

Local Institution - 0274, Seattle, Washington

Local Institution - 0012, Ciudad Autonoma Beunos Aires, Buenos Aires

Local Institution - 0015, La Plata, Buenos Aires

Local Institution - 0020, Buenos Aires, Ciudad Autónoma De Buenos Aires

Local Institution - 0294, Córdoba, Cordoba

Local Institution - 0303, Río Cuarto, Cordoba

Local Institution - 0011, Caba, Distrito Federal

Local Institution - 0008, Capital Federal, Distrito Federal

Local Institution - 0013, Ciudad Autonoma de Buenos Aires, Distrito Federal

Local Institution - 0014, Rosario Santa Fe, Santa FE

Local Institution - 0021, Cordoba, Not set

Local Institution, La Rioja, Not set

Local Institution, Viedma, Not set

Local Institution - 0071, North Sydney, New South Wales

Local Institution - 0069, Port Macquarie, New South Wales

Local Institution - 0072, Herston, Queensland

Local Institution - 0067, Elizabeth Vale, South Australia

Local Institution - 0066, Clayton, Victoria

Local Institution - 0142, Clayton, Victoria

Local Institution - 0070, Melbourne, Victoria

Local Institution - 0068, North Ballarat, Victoria

Local Institution - 0045, Graz, Not set

Local Institution - 0042, Innsbruck, Not set

Local Institution - 0048, Salzburg, Not set

Local Institution - 0046, Wien, Not set

Local Institution - 0047, Wien, Not set

Local Institution - 0187, Brussels, Not set

Local Institution - 0030, Charleroi, Not set

Local Institution - 0037, Edegem, Not set

Local Institution - 0032, Gent, Not set

Local Institution - 0031, Liege, Not set

Local Institution - 0130, Fortaleza, Ceara

Local Institution - 0225, Brasilia, Distrito Federal

Local Institution - 0287, Goiânia, Goias

Local Institution - 0133, Belo Horizonte, Minas Gerais

Local Institution - 0132, Ijui, RIO Grande DO SUL

Local Institution - 0288, Porto Alegre, RIO Grande DO SUL

Local Institution - 0131, Porto Alegre, Rio Grande Do Sul

Local Institution - 0135, Porto Alegre, RIO Grande DO SUL

Local Institution - 0273, Santa Cruz do Sul, Rio Grande Do Sul

Local Institution - 0134, Barretos, SAO Paulo

Local Institution - 0272, São Paulo, SAO Paulo

Local Institution - 0128, Santo André, São Paulo

Local Institution - 0129, Rio de Janeiro, Not set

Local Institution - 0144, São Paulo, Not set

Local Institution - 0104, São Paulo, Not set

Local Institution - 0194, Montreal, Quebec

Local Institution - 0095, Montréal, Quebec

Local Institution - 0058, Sherbrooke, Quebec

Local Institution - 0197, La Serena, Coquimbo

Local Institution - 0016, Santiago de Chile, Metropolitana

Local Institution - 0019, Santiago Region Metropolitana, Metropolitana

Local Institution - 0318, Santiago, Metropolitana

Local Institution - 0018, Vina del Mar, Valparaiso

Local Institution - 0326, Antofagasta, Not set

Local Institution - 0235, Bengbu, Anhui

Local Institution - 0239, Hefei, Anhui

Local Institution, Beijing, Beijing

Local Institution - 0319, Chongqing, Chongqing

Local Institution - 0232, Chongqing, Chongqing

Local Institution - 0267, Guangzhou, Guangdong

Local Institution - 0241, Guangzhou, Guangdong

Local Institution, Guangzhou, Guangdong

Local Institution - 0312, Zunyi, Guizhou

Local Institution - 0240, Shjiazhuang, Hebei

Local Institution - 0250, Wuhan, Hebei

Local Institution - 0248, Harbin, Heilongjiang

Local Institution, Zhengzhou, Henan

Local Institution - 0255, Changchun, Jilin

Local Institution - 0247, Changchun, Jilin

Local Institution - 0252, Shenyang, Liaoning

Local Institution - 0263, Xian, Shan3xi

Local Institution - 0245, Jinan, Shandong

Local Institution - 0256, Qingdao, Shandong

Local Institution - 0214, YanTai, Shandong

Local Institution - 0127, Shanghai, Shanghai

Local Institution - 0244, Chengdu, Sichuan

Local Institution - 0254, Tianjin, Tianjin

Local Institution - 0311, Urumqi, Xinjiang

Local Institution - 0238, Hangzhou, Zhejiang

Local Institution - 0231, Hangzhou, Zhejiang

Local Institution - 0237, Hangzhou, Zhejiang

Local Institution - 0215, Beijing, Not set

Local Institution - 0261, Barranquilla, Atlántico

Local Institution - 0203, Colombia, Bogota

Local Institution - 0113, Montería, Córdoba

Local Institution - 0094, Bogotá, Distrito Capital De Bogotá

Local Institution - 0098, Piedecuesta, Santander

Local Institution - 0093, Cali, Not set

Local Institution - 0271, Pereira, Not set

Local Institution - 0202, Rionegro, Not set

Local Institution - 0100, Hradec Kralove, Not set

Local Institution - 0103, Novy Jicin, Not set

Local Institution - 0101, Olomouc, Not set

Local Institution - 0099, Praha 10, Not set

Local Institution - 0167, Aarhus N, Midtjylland

Local Institution - 0165, Herlev, Not set

Local Institution - 0164, Kobenhavn O, Not set

Local Institution - 0166, Naestved, Not set

Local Institution - 0001, Helsinki, Not set

Local Institution - 0160, Tampere, Not set

Local Institution - 0216, Le Mans, Sarthe

Local Institution - 0004, Besancon, Not set

Local Institution - 0024, Brest, Not set

Local Institution - 0162, Clermont-Ferrand, Not set

Local Institution - 0153, Lyon, Not set

Local Institution - 0152, Montpellier, Not set

Local Institution - 0161, Paris, Not set

Local Institution - 0195, Plerin, Not set

Local Institution - 0002, Saint Herblain, Not set

Local Institution - 0258, Strasbourg, Not set

Local Institution - 0228, Toulon Cedex, Not set

Local Institution - 0003, Villejuif, Not set

Local Institution - 0084, München, Bayern

Local Institution - 0079, Saarbruecken, Saarland

Local Institution - 0083, Berlin, Not set

Local Institution - 0112, Dresden, Not set

Local Institution - 0081, Essen, Not set

Local Institution - 0158, Frankfurt, Not set

Local Institution - 0223, Hamburg, Not set

Local Institution - 0087, Heidelberg, Not set

Local Institution - 0089, Homburg, Not set

Local Institution - 0080, Köln, Not set

Local Institution - 0196, Leipzig, Not set

Local Institution - 0111, Moenchengladbach, Not set

Local Institution - 0156, Rostock, Not set

Local Institution - 0157, Velbert, Not set

Local Institution - 0105, Würzburg, Not set

Local Institution - 0115, Hong Kong, Not set

Local Institution - 0034, Dublin 8, Dublin

Local Institution - 0035, Beaumont, Not set

Local Institution - 0036, Cork, Not set

Local Institution - 0191, Catanzaro, Not set

Local Institution - 0207, Milano, Not set

Azienda Ospedaliero Universitaria Federico II di Napoli, Napoli, Not set

Local Institution - 0124, Napoli, Not set

Local Institution - 0155, Padova, Not set

Fondazione Irccs - Policlinico San Matteo, Pavia, Not set

Local Institution - 0190, Roma, Not set

Local Institution - 0125, Rozzano (MI), Not set

Local Institution - 0325, Seongnam, Not set

Local Institution - 0295, Seoul, Not set

Local Institution - 0320, Seoul, Not set

Local Institution - 0290, Seoul, Not set

Local Institution - 0291, Seoul, Not set

Local Institution - 0262, Tijuana, BAJA California

Local Institution - 0168, Mexico City, Distrito Federal

Local Institution - 0154, Mexico City, Distrito Federal

Local Institution - 0330, Zapopan, Jalisco

Local Institution - 0137, Monterrey, Nuevo LEON

Local Institution - 0212, Merida, Yucatán

Local Institution - 0280, Campeche, Not set

Local Institution - 0091, Chihuahua, Not set

Local Institution - 0145, Colima, Not set

Local Institution - 0141, Oaxaca, Not set

Local Institution - 0033, Amsterdam, Not set

Local Institution - 0177, Breda, Not set

Local Institution - 0199, Deventer, Not set

Local Institution - 0147, Utrecht, Not set

Local Institution - 0335, Bydgoszcz, Not set

Local Institution - 0061, Koszalin, Not set

Local Institution - 0059, Krakow, Not set

Local Institution - 0063, Lodz, Not set

Local Institution - 0062, Opole, Not set

Local Institution - 0060, Warszawa, Not set

Local Institution - 0334, Gliwice, Śląskie

Local Institution - 0210, Lisboa, Not set

Local Institution - 0211, Lisboa, Not set

Local Institution - 0209, Porto, Not set

Local Institution - 0110, Ponce, Not set

Local Institution - 0029, Bucharest, Not set

Local Institution - 0270, Bucharest, Not set

Local Institution - 0025, Bucuresti, Not set

Local Institution - 0028, Craiova, Not set

Local Institution - 0027, Floresti, Not set

Local Institution - 0026, Suceava, Not set

Local Institution, Krasnodar, Not set

Local Institution - 0119, Moscow, Not set

Local Institution, Moscow, Not set

Local Institution - 0285, Moskva, Not set

Local Institution, Ryazan, Not set

Local Institution - 0284, Saint Petersburg, Not set

Local Institution - 0306, Sankt-Peterburg, Not set

Local Institution, Sochi, Not set

Local Institution - 0078, Singapore, Not set

Local Institution - 0076, Singapore, Not set

Local Institution - 0077, Singapore, Not set

Local Institution - 0205, Elche, Alicante

Local Institution - 0171, Barcelona, Not set

Local Institution - 0172, Barcelona, Not set

Local Institution - 0173, Madrid, Not set

Local Institution - 0176, Madrid, Not set

Local Institution - 0169, Malaga, Not set

Local Institution - 0204, Pamplona, Not set

Local Institution - 0174, Santiago de Compostela, Not set

Local Institution - 0170, Sevilla, Not set

Local Institution - 0175, Valencia, Not set

Local Institution - 0184, Basel, Not set

Local Institution - 0186, Lausanne, Not set

Local Institution - 0185, Thun, Not set

Local Institution - 0301, Kaohsiung, Not set

Local Institution - 0300, Tainan City, Not set

Local Institution - 0298, Tainan, Not set

Local Institution - 0305, Taipei, Not set

Local Institution - 0297, Taipei, Not set

Local Institution - 0073, Adana, Not set

Local Institution - 0257, Ankara, Not set

Local Institution - 0075, Antalya, Not set

Local Institution - 0074, Istanbul, Not set

Local Institution - 0006, Withington, Manchester

Local Institution - 0005, London, Not set

Conditions: Breast Cancer

Learn More ›

Emapalumab Prevention of CAR-T Cell Associated Toxicities

NCT06550141

Recruiting

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/16/2024

Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations

Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma

Learn More ›

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

NCT05521984

Recruiting

This is a pilot phase Ib study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by it... Read More

Gender:

ALL

Ages:

Between 6 years and 21 years

Trial Updated:

12/16/2024

Locations: Washington University School of Medicine/St. Louis Children's Hospital, Saint Louis, Missouri

Conditions: Pediatric Brain Tumor, Pediatric Solid Tumor

Learn More ›

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

NCT06326463

Recruiting

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies... Read More

Gender:

ALL

Ages:

21 years and below

Trial Updated:

12/16/2024

Locations: St. Jude Children's Research Hospital, Memphis, Tennessee

Conditions: Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma, MDS

Learn More ›

Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma

NCT05996185

Recruiting

Single- arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/16/2024

Locations: Yale Cancer Center, Clinical Trials Office, New Haven, Connecticut

Conditions: T Cell Lymphoma

Learn More ›

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

NCT06738368

Not Yet Recruiting

This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by st... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/12/2024

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia

Learn More ›

Scleroderma Treatment With Autologous Transplant (STAT) Study

NCT01413100

Completed

This phase II trial studies how well giving cyclophosphamide and anti-thymocyte globulin together followed by peripheral blood stem cell transplant (PBSCT) and mycophenolate mofetil works in treating patients with systemic scleroderma (SSc). Stem cells are collected from the patient's blood and stored prior to treatment. To store the stem cells patients are given colony-stimulating factors, such as filgrastim (G-CSF) or chemotherapy (cyclophosphamide) to help stem cells move from the bone marrow... Read More

Gender:

ALL

Ages:

70 years and below

Trial Updated:

12/12/2024

Locations: City of Hope Comprehensive Cancer Center, Duarte, California +11 locations

Conditions: Systemic Scleroderma

Learn More ›

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

NCT03101748

Active Not Recruiting

This phase I/II trial studies the side effect and best dose of neratinib and to see how well it works with paclitaxel and with or without pertuzumab and trastuzumab before combination chemotherapy in treating patients with breast cancer that has spread to other places in the body (metastatic). Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with pertuzumab and trastuzumab, may induce changes in body's immune system and may interf... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/11/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma

Learn More ›

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

NCT04083170

Terminated

This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white blood cells, can take a while to recover, putting the patient at increased risk of infection. Dilanubicel consists of blood stem cells that help to produce mature blood cells, including immune cells. Drugs used in che... Read More

Gender:

ALL

Ages:

Between 6 months and 65 years

Trial Updated:

12/11/2024

Locations: University of California San Francisco, San Francisco, California +4 locations

Conditions: Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Refractory Anemia, HIV Infection

Learn More ›

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

NCT06318897

Recruiting

To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/11/2024

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer

Learn More ›